1. Detailed exploration of pathophysiology involving inflammatory status and bleeding symptoms between lipopolysaccharide- and tissue factor-induced disseminated intravascular coagulation in rats.
- Author
-
Suga Y, Kubo A, Katsura H, Staub Y, Tashiro K, Yamada S, Morishita E, and Asakura H
- Subjects
- Animals, Biomarkers, Blood Coagulation, Blood Coagulation Tests, Disease Models, Animal, Disseminated Intravascular Coagulation blood, Disseminated Intravascular Coagulation diagnosis, Hemorrhage diagnosis, Humans, Male, Prognosis, Rats, Disease Susceptibility, Disseminated Intravascular Coagulation complications, Disseminated Intravascular Coagulation etiology, Hemorrhage etiology, Hemorrhage metabolism, Lipopolysaccharides adverse effects, Thromboplastin adverse effects
- Abstract
Lipopolysaccharide (LPS) and tissue factor (TF) have frequently been used to induce disseminated intravascular coagulation (DIC) in experimental animal models. We have previously reported that the pathophysiology of DIC differs according to the inducing agents. However, inflammatory status and bleeding symptoms have not been fully compared between rat models of the two forms of DIC. We attempted to evaluate detailed characteristic features of LPS- and TF-induced DIC models, especially in regard to inflammatory status and bleeding symptoms, in addition to selected hemostatic parameters and pathologic findings in the kidneys. The degree of hemostatic activation in both types of experimental DIC was identical, based on the results of thrombin-antithrombin complex levels. Markedly elevated tumor necrosis factor, interleukin-6, and high-mobility group box-1 concentrations were observed with severe organ dysfunction and marked fibrin deposition in the kidney on administration of LPS, whereas markedly elevated D-dimer concentration and bleeding symptoms were observed with TF administration. Pathophysiology such as fibrinolytic activity, organ dysfunction, inflammation status, and bleeding symptom differed markedly between LPS- and TF-induced DIC models in rats. We, therefore, recommend that these disease models be assessed carefully as distinct entities to determine the implications of their experimental and clinical use., (© 2021. Japanese Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF